<DOC>
	<DOCNO>NCT02325440</DOCNO>
	<brief_summary>A trial patient relapse remit multiple sclerosis ( RRMS ) Main objective : - To evaluate change reconstitution immune surveillance time upon switch natalizumab fingolimod assess change expression CD49d . - To evaluate change migratory capacity immune cells/peripheral blood mononuclear cell ( PBMCs ) upon switch natalizumab fingolimod in-vitro model blood-brain-barrier ( BBB ) . - To evaluate change paraclinical disease activity time upon switch natalizumab fingolimod assess MRI ( change Gd+ , T2w lesion DTI ) . - To evaluate change T1w / FLAIR lesion upon switch natalizumab fingolimod .</brief_summary>
	<brief_title>Study Assess Immune Function MRI Disease Activity RRMS Patients When Switching From Natalizumab Gilenya</brief_title>
	<detailed_description>Patients screen must sign informed consent visit 1 . At 2nd visit , patient receive baseline infusion Natalizumab , follow 8 week washout Phase . After washout Phase patient receive fingolimod 32 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>1 . Written informed consent must obtain assessment perform . 2 . Male female subject age 1865 yr . 3 . Subjects RRMS , define 2010 rev . McDonald criterion . 4 . Patients ( EDSS ) score 06.0 inclusive . 5 . Patients treatment natalizumab ≥ 12 month prior screen treatment discontinuation consider following reason : treatment duration 2 year positive JC virus ( JCV ) antibody status adverse effect include hypersensitivity reaction presence antinatalizumab neutralize antibody valid medical reason 1 . Patients history chronic disease immune system MS , require systemic immunosuppressive treatment , know immunodeficiency syndrome . 2 . Patients Crohn´s disease ulcerative colitis . 3 . Patients treat : systemic corticosteroid immunoglobulin within 1 month prior baseline . immunosuppressive medication azathioprine , cyclophosphamide methotrexate within 3 month prior baseline . monoclonal antibody ( exclude natalizumab ) within 3 month prior baseline . cladribine mitoxantrone time . 4 . History malignancy organ system ( cutaneous basal cell carcinoma ) . 5 . Uncontrolled diabetes mellitus ( HbA1c &gt; 7 % ) . 6 . Diagnosis macular edema Screening Phase . 7 . Severe active infection , active chronic infection . 8 . Negative varicellazoster virus immunoglobulin G antibodies prior baseline . 9 . Patients receive live liveattenuated vaccine ( include varicellazoster virus measles ) within 1 month prior baseline . 10 . Patients receive total lymphoid irradiation bone marrow transplantation . 11 . Patients medically unstable condition , assess investigator . 12 . Patients certain cardiovascular condition and/or finding screen ECG . 13 . Patients certain lung disease . 14 . Patients certain hepatic condition . 15 . Patients screen white blood cell ( WBC ) count &lt; 3,500/mm3 lymphocyte count &lt; 800/mm3 . 16 . Patients certain neurologic/psychiatric disorder : 17 . Patients unable undergo MRI scan , include claustrophobia history hypersensitivity gadoliniumdiethylenetriaminepentacetate ( GdDTPA ) . 18 . Patients receive investigational drug therapy within 180 day 5 halflives baseline , whichever longer . 19 . Pregnant nursing ( lactate ) woman , confirm positive human chorionic gonadotropin laboratory . 20 . Women childbearing potential unless use effective contraception study 5 halflives stop treatment . In case use oral contraception woman stable medication minimum 3 month baseline . 21 . History hypersensitivity study drug drug similar chemical class . 22 . Prior participation trial fingolimod .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>RRMS ( relapse remit multiple sclerosis )</keyword>
	<keyword>Cluster differentiation 49d ( CD49d )</keyword>
	<keyword>immune function</keyword>
	<keyword>disease activity</keyword>
</DOC>